The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it will open a randomized, registration-enabling phase 2/3 clinical trial to evaluate ivonescimab combined with chemotherapy as ...
A simple blood test that detects tumor cells circulating in the blood shows promise as a new way to predict high or low risk of a breast cancer relapse. This is according to data presented today at ...
The new phase 3 RxFINE-Low trial will test whether patients with low genomic risk but high anatomic risk early-stage breast ...
The BRCA founder outreach study: Initial results of a digital health model. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This abstract does not include a full text component.
Patient enrollment has opened for the COMmunication and Education in Tumor Profiling COMET study, the ECOG-ACRIN Cancer Research Group has announced. The study will determine if online genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results